{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T05:50:22Z","timestamp":1771653022111,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016619","name":"MyoKardia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.clinthera.2021.11.006","type":"journal-article","created":{"date-parts":[[2021,12,12]],"date-time":"2021-12-12T15:10:06Z","timestamp":1639321806000},"page":"52-66.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit"],"prefix":"10.1016","volume":"44","author":[{"given":"Nihar","family":"Desai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jipan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan B.","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Whang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer T.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9468-4989","authenticated-orcid":false,"suffix":"Jr","given":"Louis P.","family":"Garrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.11.006_bib0001","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1161\/CIRCULATIONAHA.119.042339","article-title":"Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy","volume":"141","author":"Toepfer","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0002","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12551-017-0274-6","article-title":"Hypertrophic cardiomyopathy and the myosin mesa: viewing an old disease in a new light","volume":"10","author":"Trivedi","year":"2018","journal-title":"Biophys Rev"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0003","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0004","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0005","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/hrt.2005.068577","article-title":"Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy","volume":"92","author":"Elliott","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0006","first-page":"1","article-title":"Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0007","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0008","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/ejhf.541","article-title":"Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives","volume":"18","author":"Ammirati","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0009","first-page":"896","article-title":"A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy","volume":"3","author":"Liebregts","year":"2015","journal-title":"JACC: Heart Failure"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0010","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jtcvs.2018.08.062","article-title":"Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a propensity score\u2013matched cohort","volume":"157","author":"Nguyen","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0011","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamacardio.2016.0252","article-title":"Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US nationwide inpatient database, 2003-2011","volume":"1","author":"Kim","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0012","doi-asserted-by":"crossref","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","article-title":"Deciphering the super relaxed state of human beta-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers","volume":"115","author":"Anderson","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0013","doi-asserted-by":"crossref","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","article-title":"A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle","volume":"292","author":"Kawas","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0014","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1080\/00498254.2018.1495856","article-title":"In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin","volume":"49","author":"Grillo","year":"2019","journal-title":"Xenobiotica"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0015","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0016","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0735-1097(21)01891-X","article-title":"Long-term safety of mavacamten in patients with obstructive hypertrophic cardiomyopathy: interim results of the mava-long term extension (LTE) study","volume":"77","author":"Rader","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0017","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/eurheartj\/eht070","article-title":"Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy","volume":"34","author":"Coats","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0018","first-page":"A14251","article-title":"Abstract 14251: Peak oxygen consumption is an independent predictor of survival and outcomes in obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) patients: results from the International Sarcomeric Human Cardiomyopathies Registry (SHaRe)","volume":"138","author":"Tompkins","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0019","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00392-018-1209-3","article-title":"Risk marker profiles in patients treated with percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy","volume":"107","author":"Burghardt","year":"2018","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0020","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1093\/eurheartj\/ehx527","article-title":"Women with hypertrophic cardiomyopathy have worse survival","volume":"38","author":"Geske","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0021","doi-asserted-by":"crossref","first-page":"152","DOI":"10.5830\/CVJA-2015-075","article-title":"Clinical features, spectrum of causal genetic mutations and outcome of hypertrophic cardiomyopathy in South Africans","volume":"27","author":"Ntusi","year":"2016","journal-title":"Cardiovasc J Afr"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0022","article-title":"Latent outflow tract obstruction in hypertrophic cardiomyopathy: clinical characteristics and outcomes of septal myectomy","author":"Cui","year":"2020","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0023","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/hrt.2006.095232","article-title":"Prognosis and prognostic factors in patients with hypertrophic cardiomyopathy in Japan: results from a nationwide study","volume":"93","author":"Nasermoaddeli","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0024","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1161\/CIRCULATIONAHA.108.798314","article-title":"Syncope and risk of sudden death in hypertrophic cardiomyopathy","volume":"119","author":"Spirito","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0025","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJMoa021332","article-title":"Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy","volume":"348","author":"Maron","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0026","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.4103\/0366-6999.157656","article-title":"Clinical characteristics and prognosis of end-stage hypertrophic cardiomyopathy","volume":"128","author":"Xiao","year":"2015","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0027","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/eurheartj\/ehl041","article-title":"Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy","volume":"27","author":"Elliott","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0028","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJMoa021332","article-title":"Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy","volume":"348","author":"Maron","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0029","doi-asserted-by":"crossref","first-page":"e3531","DOI":"10.1097\/MD.0000000000003531","article-title":"Cost-effectiveness of eplerenone compared to usual care in patients with chronic heart failure and NYHA class II symptoms, an Australian perspective","volume":"95","author":"Ademi","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0030","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/11315730-000000000-00000","article-title":"The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy","volume":"9","author":"Pradelli","year":"2009","journal-title":"Am J Cardiovasc Drug"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0031","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.amjmed.2003.07.016","article-title":"Economic effects of beta-blocker therapy in patients with heart failure","volume":"116","author":"Cowper","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0032","doi-asserted-by":"crossref","first-page":"36","DOI":"10.21037\/cdt.2016.11.23","article-title":"Outcomes in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a survival meta-analysis","volume":"7","author":"Masri","year":"2017","journal-title":"Cardiovas Diag Ther"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0033","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0034","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1177\/0272989X16656165","article-title":"Changing cycle lengths in state-transition models: challenges and solutions","volume":"36","author":"Chhatwal","year":"2016","journal-title":"Med Decis Making"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0035","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jacc.2009.01.079","article-title":"Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study","volume":"54","author":"Sorajja","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0036","unstructured":"Arias E. United States Life Tables, 2010. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.2014;63:1\u201363."},{"key":"10.1016\/j.clinthera.2021.11.006_bib0037","series-title":"New York Heart Association functional class and mortality in obstructive hypertrophic cardiomyopathy","author":"Lakdawala","year":"2021"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0038","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jval.2019.02.009","article-title":"United States valuation of EQ-5D-5L health states using an international protocol","volume":"22","author":"Pickard","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0039","series-title":"Paper presented at: Virtual ISPOR","article-title":"Health utilities among patients with obstructive hypertrophic cardiomyopathy (oHCM): an analysis of patient health-related quality of life in the EXPLORER-HCM trial","author":"Xie","year":"2021"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0040","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Spertus","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0041","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","article-title":"Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy","volume":"143","author":"Saberi","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0042","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jchf.2014.11.011","article-title":"Cardiopulmonary responses and prognosis in hypertrophic cardiomyopathy: a potential role for comprehensive noninvasive hemodynamic assessment","volume":"3","author":"Finocchiaro","year":"2015","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0043","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.echo.2008.11.001","article-title":"Prognostic significance of left atrial volume dilatation in patients with hypertrophic cardiomyopathy","volume":"22","author":"Losi","year":"2009","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0044","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.ahj.2007.06.026","article-title":"Life expectancy gains and cost-effectiveness of implantable cardioverter\/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy","volume":"154","author":"You","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0045","first-page":"330","article-title":"Entresto (sacubitril\/valsartan): first-in-class angiotensin receptor neprilysin inhibitor FDA approved for patients with heart failure","volume":"8","author":"Fala","year":"2015","journal-title":"Am Health Drug Benefit"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0046","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamacardio.2016.1747","article-title":"Cost-effectiveness analysis of sacubitril\/valsartan vs enalapril in patients with heart failure and reduced ejection fraction","volume":"1","author":"Gaziano","year":"2016","journal-title":"JAMA Cardiology"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0047","unstructured":"US FDA. PRALUENT\u00ae (alirocumab) injection, for subcutaneous use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125559s002lbl.pdf. 2017."},{"key":"10.1016\/j.clinthera.2021.11.006_bib0048","unstructured":"US FDA. REPATHA (evolocumab) injection, for subcutaneous use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125522orig2s000lbl.pdf. 2021."},{"key":"10.1016\/j.clinthera.2021.11.006_bib0049","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s10741-019-09874-2","article-title":"Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review","volume":"25","author":"Azari","year":"2020","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0050","article-title":"Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies","author":"Rozenbaum","year":"2021","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0051","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1161\/CIRCULATIONAHA.111.054072","article-title":"Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis","volume":"125","author":"Reynolds","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2021.11.006_bib0052","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jval.2017.12.009","article-title":"A health economics approach to US value assessment frameworks-summary and recommendations of the ISPOR special task force report [7]","volume":"21","author":"Garrison","year":"2018","journal-title":"Value Health"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821004604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821004604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:57:00Z","timestamp":1758963420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821004604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0149291821004604"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.11.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}